The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 17, 2017

Filed:

Oct. 27, 2014
Applicant:

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Jennafer Dotson, Belmont, CA (US);

Robert Andrew Heald, Harlow, GB;

Timothy Heffron, Burlingame, CA (US);

Graham Elgin Jones, Harlow, GB;

Sussie Lerche Krintel, Harlow, GB;

Neville James McLean, Harlow, GB;

Chudi Ndubaku, San Francisco, CA (US);

Alan G. Olivero, Half Moon Bay, CA (US);

Laurent Salphati, San Francisco, CA (US);

Lan Wang, Foster City, CA (US);

BinQuing Wei, Belmont, CA (US);

Assignee:

Genentech, Inc., South San Francisco, unknown;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/14 (2006.01); C07D 471/22 (2006.01); C07D 487/14 (2006.01); C07D 498/14 (2006.01); C07D 491/14 (2006.01); C07D 495/14 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); A61K 31/5386 (2006.01); A61K 39/395 (2006.01); C07D 491/147 (2006.01); C07D 498/20 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07D 498/14 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/5386 (2013.01); A61K 39/3955 (2013.01); C07D 487/14 (2013.01); C07D 491/14 (2013.01); C07D 491/147 (2013.01); C07D 495/14 (2013.01); C07D 498/20 (2013.01); A61K 2039/505 (2013.01); C07D 471/14 (2013.01); C07D 471/22 (2013.01);
Abstract

Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.


Find Patent Forward Citations

Loading…